These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 30344066)
1. Staggering the administration of polymyxin B and meropenem in time-kill against carbapenem-resistant Enterobacteriaceae exhibiting a wide range of meropenem MICs. Kulengowski B; Clark JA; Burgess DS Diagn Microbiol Infect Dis; 2019 Mar; 93(3):261-264. PubMed ID: 30344066 [TBL] [Abstract][Full Text] [Related]
2. Synergy of polymyxin B, tigecycline and meropenem against carbapenem-resistant Enterobacter cloacae complex isolates. Alves PH; Boff RT; Barth AL; Martins AF Diagn Microbiol Infect Dis; 2019 May; 94(1):81-85. PubMed ID: 30638946 [TBL] [Abstract][Full Text] [Related]
3. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model. Barber KE; Pogue JM; Warnock HD; Bonomo RA; Kaye KS J Antimicrob Chemother; 2018 Sep; 73(9):2405-2410. PubMed ID: 29939267 [TBL] [Abstract][Full Text] [Related]
4. Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae. Kulengowski B; Rutter WC; Campion JJ; Lee GC; Feola DJ; Burgess DS Diagn Microbiol Infect Dis; 2018 Nov; 92(3):262-266. PubMed ID: 30098852 [TBL] [Abstract][Full Text] [Related]
5. Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. Pascale R; Giannella M; Bartoletti M; Viale P; Pea F Expert Rev Anti Infect Ther; 2019 Oct; 17(10):819-827. PubMed ID: 31559876 [No Abstract] [Full Text] [Related]
6. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222 [No Abstract] [Full Text] [Related]
7. Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin. Kulengowski B; Clark JA; Burgess DS Diagn Microbiol Infect Dis; 2019 Apr; 93(4):372-375. PubMed ID: 30514595 [TBL] [Abstract][Full Text] [Related]
8. Deciphering polymyxin B minimum inhibitory concentration from colistin minimum inhibitory concentration and vice versa: An analysis on 156 carbapenem-resistant Behera B; Jena J; Kar P; Mohanty S; Mahapatra A Indian J Med Microbiol; 2018; 36(4):587-589. PubMed ID: 30880712 [TBL] [Abstract][Full Text] [Related]
10. Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an Sabet M; Tarazi Z; Rubio-Aparicio D; Nolan TG; Parkinson J; Lomovskaya O; Dudley MN; Griffith DC Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133570 [TBL] [Abstract][Full Text] [Related]
11. What's Lurking Around the Corner? Polymyxin B Resistance Among Klebsiella pnemoniae carbapenemase-producing Enterobacteriaceae, and Others, as a Burden of Use. Perez LRR Infect Control Hosp Epidemiol; 2017 Sep; 38(9):1120-1121. PubMed ID: 28693659 [No Abstract] [Full Text] [Related]
12. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study. Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229 [TBL] [Abstract][Full Text] [Related]
13. Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient. Jorgensen SCJ; McDonald P; Mynatt RP; Pogue JM; Lerner SA; Dhar S; Salimnia H; Rybak MJ J Antimicrob Chemother; 2018 Dec; 73(12):3529-3531. PubMed ID: 30188993 [No Abstract] [Full Text] [Related]
14. Effect of the meropenem MIC on the killing activity of meropenem and polymyxin B in combination against KPC-producing Klebsiella pneumoniae. Kulengowski B; Campion JJ; Feola DJ; Burgess DS J Antibiot (Tokyo); 2017 Aug; 70(9):974-978. PubMed ID: 28676713 [No Abstract] [Full Text] [Related]
15. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Kinn PM; Chen DJ; Gihring TM; Schulz LT; Fox BC; McCreary EK; Lepak AJ Diagn Microbiol Infect Dis; 2019 Mar; 93(3):258-260. PubMed ID: 30344065 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189 [TBL] [Abstract][Full Text] [Related]
18. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Lee YR; Baker NT Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787 [TBL] [Abstract][Full Text] [Related]
19. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. Jorgensen SCJ; Rybak MJ Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523 [TBL] [Abstract][Full Text] [Related]
20. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]